Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Find out more about five biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human ...

Investors in weight-loss drug companies like Novo Nordisk and Eli Lilly face concerns over side effects and market ...

For those conducting R&D into developing a new form of weight loss therapy, the most obvious target is the development of an oral treatment. As such, there is a race by major obesity drug ...

Eli Lilly’s CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as ...

Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform. | ...

Now that Mounjaro has been authorised for use on the NHS, it will be key that access to specialist weight loss services is ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A new study shows semaglutide medications, such as Ozempic and Wegovy, may be effective in treating hidradenitis suppurativa ...

Research explores how excessive sugar consumption can drive systemic inflammation, disrupt the gut and oral microbiomes, and ...

Nasdaq-listed Amneal Pharmaceuticals, which already operates multiple manufacturing facilities in Gujarat, is further ...